BR9710486A - Composto, forma de dosagem de unidade farmacêutica, e, processo terapêutico para inibir crescimento de célula em um sujeito em necessidade de tal terapia. - Google Patents

Composto, forma de dosagem de unidade farmacêutica, e, processo terapêutico para inibir crescimento de célula em um sujeito em necessidade de tal terapia.

Info

Publication number
BR9710486A
BR9710486A BR9710486-8A BR9710486A BR9710486A BR 9710486 A BR9710486 A BR 9710486A BR 9710486 A BR9710486 A BR 9710486A BR 9710486 A BR9710486 A BR 9710486A
Authority
BR
Brazil
Prior art keywords
alkyl
absent
aryl
therapy
subject
Prior art date
Application number
BR9710486-8A
Other languages
English (en)
Inventor
Trevor C Mcmorris
Michael J Kelner
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9710486A publication Critical patent/BR9710486A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/37—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed system having three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
    • C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C07C49/737—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system having three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/757—Unsaturated compounds containing a keto groups being part of a ring containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSTO, FORMA E DOSAGEM DE UNIDADE FARMACêUTICA, E, PROCESSO TERAPêUTICO PARA INIBIR CRESCIMENTO DE CéLULA DE TUMOR EM UM SUJEITO EM NECESSIDADE DE TAL TERAPIA". A presente invenção fornece análogos de iludina de fórmula geral (I): onde R~ 1~ é (CH~ 2~)~ n~-X-Y ou H; n é 0 a 4; X é O ou N ou ausente; e Y é um (C~ 1~-C~ 8~) alquil opcionalmente substituído, (C~ 6~-C~ 10)aril, (C~ 6~-C~ 10~)aril(C~ 1~-C~ 4~)alquil ou ciclo (C~ 3~-C~ 6~)alquil compreendendo opcionalmente um ou mais heteroátomos; um monossacarídeo, um resíduo de amino ácido, ou H quando n é 2-4; R~ 2~ está ausente; ou R~ 1~ e R~ 2~ juntos compreendem um anel cíclico de 5-7 elementos; R~ 3~ é H, SCH~ 2~CO~ 2~(C~ 1~-C~ 2~(C~ 1~-C~ 4~)alquil, O-(c~ 5~-C~ 12~)aril ou -S-(C~ 5~-C~ 12~)aril; R~ 5~ é H, OH ou ausente; R~ 6~ é (C~ 1~-C~ 4~)alquil ou ausentes; r~ 7~ é OH ou OSI((C~ 1~-C~ 4~)alquil)~ 3~; ou R~ 6~ e R~ 7~ juntos são etilenodióxi; R~ 8~ é (C~ 1~-C~ 8~) alquil opcionlamente substituído; e as ligações representadas por --- estão individualmente presentes ou ausentes. A invenção fornece adicionalmente dímeros compreendendo análogos para fórmula (I).
BR9710486-8A 1996-07-18 1997-07-14 Composto, forma de dosagem de unidade farmacêutica, e, processo terapêutico para inibir crescimento de célula em um sujeito em necessidade de tal terapia. BR9710486A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/683,687 US5932553A (en) 1996-07-18 1996-07-18 Illudin analogs useful as antitumor agents
PCT/US1997/012143 WO1998003458A1 (en) 1996-07-18 1997-07-14 Illudin analogs useful as antitumor agents

Publications (1)

Publication Number Publication Date
BR9710486A true BR9710486A (pt) 2000-01-11

Family

ID=24745052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710486-8A BR9710486A (pt) 1996-07-18 1997-07-14 Composto, forma de dosagem de unidade farmacêutica, e, processo terapêutico para inibir crescimento de célula em um sujeito em necessidade de tal terapia.

Country Status (24)

Country Link
US (7) US5932553A (pt)
EP (2) EP0915819B1 (pt)
JP (1) JP4372843B2 (pt)
KR (1) KR100627746B1 (pt)
CN (1) CN100349845C (pt)
AP (2) AP1250A (pt)
AT (2) ATE267791T1 (pt)
AU (1) AU738991B2 (pt)
BR (1) BR9710486A (pt)
CA (1) CA2260926C (pt)
CZ (1) CZ297803B6 (pt)
DE (2) DE69729302T2 (pt)
DK (1) DK0915819T3 (pt)
ES (2) ES2293122T3 (pt)
HK (2) HK1019873A1 (pt)
HU (1) HU226890B1 (pt)
IL (1) IL128058A (pt)
NO (1) NO316444B1 (pt)
NZ (1) NZ333857A (pt)
OA (1) OA10957A (pt)
PL (1) PL189726B1 (pt)
PT (1) PT915819E (pt)
WO (1) WO1998003458A1 (pt)
ZA (1) ZA976242B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932553A (en) * 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) * 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
CA2291710A1 (en) * 1997-05-22 1998-11-26 Tatsuya Tamaoki Bisaryl compounds and cancer remedies containing the same
US7141603B2 (en) * 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6025328A (en) * 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US6436916B1 (en) 2000-10-12 2002-08-20 Alvin Guttag Ibuprofen-aspirin and hydroxymethylacylfulvene analogs
US7015247B2 (en) * 2000-10-12 2006-03-21 Alvin Guttag Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs
US7718385B2 (en) * 2003-10-17 2010-05-18 The Johns Hopkins University Bioactivation of alkylating agents for cancer treatment
US20050274274A1 (en) * 2004-06-14 2005-12-15 Gore Makarand P Methods and compositions for dying a substrate
JP4989648B2 (ja) * 2005-08-03 2012-08-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗癌剤として有用なイルジン類似体
DE102005052501A1 (de) * 2005-11-03 2007-05-16 Univ Ernst Moritz Arndt Neue Leitstrukturen für zytostatische Verbindungen auf Basis von Spiroverbindungen
US8895667B2 (en) 2009-07-17 2014-11-25 Tyco Electronics Corporation Methods of making reversible crosslinked polymers and related methods
US10285955B2 (en) 2014-04-10 2019-05-14 Af Chemicals, Llc Affinity medicant conjugate
US11135182B2 (en) 2014-04-10 2021-10-05 Af Chemicals, Llc Affinity medicant conjugates
CN106458922A (zh) 2014-04-10 2017-02-22 Af化学药品有限责任公司 亲和药物共轭物
EP3846791A4 (en) * 2018-09-04 2022-06-08 Lantern Pharma Inc. ILLUDIN ANALOGUES, THEIR USES AND PROCEDURES FOR THEIR SYNTHESIS
US11160807B1 (en) 2018-12-11 2021-11-02 Af Chemicals, Llc Methods, compositions and devices for treating cancer with illudofulvenes
EP4035684A1 (en) 2019-11-25 2022-08-03 AF Chemical LLC Affinity illudofulvene conjugates
US11591295B2 (en) 2019-11-25 2023-02-28 Af Chemicals Llc Affinity illudofulvene conjugates
CN112972443A (zh) * 2021-03-29 2021-06-18 杭州添帆生物科技有限公司 一种抗癌药物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4612302A (en) 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
DE3470975D1 (en) * 1983-12-22 1988-06-09 Bbc Brown Boveri & Cie Zinc oxide varistor
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
JPS62234040A (ja) * 1986-04-02 1987-10-14 Kyowa Hakko Kogyo Co Ltd Ｄｃ１０４３物質
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH04502012A (ja) 1989-09-27 1992-04-09 モスコフスキ　ナウチノ―イススレドバテルスキ　インスティテュト　グラツィニフ　ボレツネイ　イメニ　ゲルムゴルツァ 進行性近視の治療用組成物
HU208115B (en) * 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
EP0565519B1 (en) 1989-10-03 1996-08-28 The Regents Of The University Of California Illudin analogs as anti-tumor agents
US5439936A (en) * 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
SG49667A1 (en) * 1993-04-27 1998-06-15 Smithkline Beecham Corp Endothelin receptor antagonists
US5708163A (en) 1994-03-15 1998-01-13 Sloan-Kettering Institute Of Cancer Research Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
US6303120B1 (en) 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
US6235789B1 (en) 1994-09-12 2001-05-22 Takeda Chemical Industries, Ltd. Benzocycloalkene compounds, their production and use
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
JPH1194239A (ja) * 1997-09-26 1999-04-09 Nippon Furnace Kogyo Kaisha Ltd 交互切換蓄熱再生バーナシステム及びその燃焼制御方法
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
JP4989648B2 (ja) * 2005-08-03 2012-08-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗癌剤として有用なイルジン類似体

Also Published As

Publication number Publication date
US5932553A (en) 1999-08-03
AU738991B2 (en) 2001-10-04
HUP9904290A2 (hu) 2000-09-28
NO990164D0 (no) 1999-01-14
AP1251A (en) 2004-02-27
AP1250A (en) 2004-02-27
US7329759B2 (en) 2008-02-12
ZA976242B (en) 1998-03-18
DE69729302D1 (de) 2004-07-01
EP1454893B1 (en) 2007-09-12
JP2000515524A (ja) 2000-11-21
US7713939B2 (en) 2010-05-11
PL189726B1 (pl) 2005-09-30
PL331151A1 (en) 1999-06-21
ATE372976T1 (de) 2007-09-15
US6380403B1 (en) 2002-04-30
US6639105B2 (en) 2003-10-28
WO1998003458A1 (en) 1998-01-29
NO990164L (no) 1999-03-17
CA2260926C (en) 2007-11-20
ATE267791T1 (de) 2004-06-15
DK0915819T3 (da) 2004-09-27
NZ333857A (en) 2000-09-29
CZ12999A3 (cs) 1999-07-14
HK1068210A1 (en) 2005-04-22
CA2260926A1 (en) 1998-01-29
DE69738145T2 (de) 2008-06-19
EP0915819A1 (en) 1999-05-19
HK1019873A1 (en) 2000-03-03
CN1230166A (zh) 1999-09-29
NO316444B1 (no) 2004-01-26
DE69729302T2 (de) 2005-04-21
KR100627746B1 (ko) 2006-09-27
EP1454893A1 (en) 2004-09-08
IL128058A0 (en) 1999-11-30
AP9901465A0 (en) 1999-03-31
KR20000067888A (ko) 2000-11-25
AU3600497A (en) 1998-02-10
OA10957A (en) 2001-10-30
US6069283A (en) 2000-05-30
PT915819E (pt) 2004-10-29
US20020161206A1 (en) 2002-10-31
US6987193B2 (en) 2006-01-17
CN100349845C (zh) 2007-11-21
ES2293122T3 (es) 2008-03-16
AP2001002315A0 (en) 2001-12-31
EP0915819B1 (en) 2004-05-26
JP4372843B2 (ja) 2009-11-25
CZ297803B6 (cs) 2007-04-04
IL128058A (en) 2007-06-03
HU226890B1 (en) 2010-01-28
DE69738145D1 (de) 2007-10-25
HUP9904290A3 (en) 2001-02-28
ES2222517T3 (es) 2005-02-01
US20080306013A1 (en) 2008-12-11
US20060194744A1 (en) 2006-08-31
US20040167100A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
BR9710486A (pt) Composto, forma de dosagem de unidade farmacêutica, e, processo terapêutico para inibir crescimento de célula em um sujeito em necessidade de tal terapia.
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
YU18593A (sh) Sredstva protiv gljivičnih oboljenja koja sadrže ciklični peptid i postupak za njihovo dobijanje
BRPI0315188B8 (pt) composto e composição farmacêutica
BG104853A (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
ES514240A0 (es) Un procedimiento para la prepracion de nuevos derivados de acidos 2-carbamimidoil-1-,carbadestiapen-2-en-3-carboxilados.
AU2246292A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
HUT55034A (en) Process for producing peptides with hemoregulating effect and pharmaceutical compositions comprising such compounds as active ingredient
WO2002007677A3 (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
IT1262921B (it) Agenti antitumorali analoghi di oligopeptidi pirrol-amidinici retroversi processi di preparazione e prodotti farmaceutici che li contengono
PT95854A (pt) Processo para a preparacao de composicoes contendo derivados de pirimidona e analogos, uteis no tratamento da asma e de certas perturbacoes da pele
BR9805053A (pt) Compostos de pirrol, um processo para sua preparação e composições farmacêuticas que os contêm.
RS50423B (sr) Novi derivati oktahidro-6,10-diokso-6h-piridazino(1,2-a) (1,2) diazepin-1-karboksilne kiseline, njihov postupak dobijanja i njihova primena za dobijanje farmaceutski aktivnih jedinjenja
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
EP1090625A3 (en) Topical composition for the skin and use thereof
HU903092D0 (en) Process for the preparation of buten-carboxylic acid derivatives and pharmaceutical compositions containing such compounds
AU3895689A (en) Cyclic sulfur-containing amino acid derivatives
HU906230D0 (en) Process for the preparation of benzanilide derivatives and medical preparations containing them
RU94032285A (ru) Цефалоспориновые соединения, способ их получения, фармацевтическая композиция
AU4953997A (en) New histidine derivatives, preparation process, and their use as free antiradical agents
FR2413358A1 (fr) Nouveaux derives de 2-aminomethylphenol, utiles notamment comme agents anti-inflammatoires, et leur procede de preparation
ES2012958A6 (es) Procedimiento para preparar derivados de cisteina.
EA200000374A2 (ru) Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AOS REQUISITOS DE NOVIDADE ( ARTIGO 8O COMBINADO COM ARTIGO 11 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]